---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-121714"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2025-05-16T23:59:59+00:00"
generated_at: "2026-05-21T03:42:27.643976+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Neumora receives Nasdaq minimum bid price deficiency notice; has until Nov 10, 2025 to cure

## Summary
- Nasdaq notified Neumora on May 14, 2025 that its stock failed to meet the $1.00 minimum bid price requirement.
- Company has 180 calendar days, until November 10, 2025, to regain compliance by closing at $1.00+ for 10 consecutive business days.
- If not compliant by Nov 10, 2025, Neumora may seek transfer to Nasdaq Capital Market and additional cure period.
- Board approved a reverse stock split (1-for-5 to 1-for-30) subject to stockholder vote at Annual Meeting on May 28, 2025.
- Neumora intends to monitor bid price and consider options including the reverse split to maintain listing.

## SEC filing metadata
- accession: 0001193125-25-121714
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2025-05-16T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000119312525121714/0001193125-25-121714-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000119312525121714/d933150d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-121714
- JSON: https://secwatch.observer/filing/0001193125-25-121714.json
- Plain text: https://secwatch.observer/filing/0001193125-25-121714.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.